00:00What is the role of medicine in the treatment of chronic diseases?
00:04As in terms of medicine, it is always said that the first form of therapy is prevention.
00:10Therefore, it is very important, when prevention fails to act, to have available therapeutic presuppositions
00:17that allow these patients affected by the chronic disease of the hands to be able to optimize a therapy
00:25that allows to greatly improve the quality of life, as well as, clearly, to bring an absolutely tangible benefit
00:34on the same goals that characterize these pathologies located exclusively in the hands.
00:41Until recently, we had an extremely limited number of therapeutic approaches
00:48that, in light and moderate forms, consisted almost exclusively of the use of products for local use,
00:57for topical use, based on molecules and corticosteroids at medium-low power,
01:03also the use of high-power corticosteroids for atomic therapy in the most serious forms,
01:09the only drug for systemic administration that was approved, many years ago, for the chronic disease of the hands,
01:19a drug that, however, has a definitely challenging safety profile for the patient,
01:26engraved also by a series of events between which, certainly, the theratogenicity.
01:34Of course, the greater understanding of the pathogenic mechanisms of this clinical framework
01:40has led to a line of development of drugs that somehow block the inflammatory mechanism
01:50and all the modulations that are at the base of these inflammatory processes of the hands,
01:55and, in particular, a lot of attention has been paid to some categories of drugs
02:03that go with a mechanism that we call a jack start, that is, a mechanism of transduction of the inflammatory signal,
02:12to make significant contributions, and, in particular, one of these drugs
02:18that was recently, at the end of September, approved by the European Agency for its Clinical Use,
02:26I am referring to Delgocitinib.
02:29Delgocitinib is a molecule that will mark an important turning point in the treatment of patients affected by chronic hand enzymes,
02:39because it is a drug for topical use, therefore, vapourized in the form of a cream,
02:44which blocks many of the mechanisms that then lead to the production of these inflammatory molecules,
02:54which are directly responsible for the damage to the cutaneous level.
02:57Delgocitinib, being a jack start, acts on many mechanisms that then lead to the formation of these inflammatory cytokines
03:07on different aspects of our immunity.
03:09This is the reason why the drug, in Phase I and II studies,
03:15conducted in 16 weeks, but also in the longest study, in 32 weeks,
03:22and the results of Phase III studies in 16 weeks,
03:29which were recently published on Lancet,
03:32in fact, I am honored to be one of the authors of this article,
03:37have shown the achievement of all the endpoints that appeared among the primary objectives of the study.
Comments